Literature DB >> 4056452

Stevens-Johnson syndrome associated with psittacosis.

M South, T G Wreghitt, E O Caul.   

Abstract

Entities:  

Mesh：

Year:  1985        PMID： 4056452     DOI： 10.1016/s0163-4453(85)92171-1

Source DB:  PubMed          Journal:  J Infect        ISSN： 0163-4453            Impact factor:   6.072


× No keyword cloud information.
  3 in total

1.  Histone H3 wild-type DIPG/DMG overexpressing EZHIP extend the spectrum diffuse midline gliomas with PRC2 inhibition beyond H3-K27M mutation.

Authors:  David Castel; Thomas Kergrohen; Arnault Tauziède-Espariat; Alan Mackay; Samia Ghermaoui; Emmanuèle Lechapt; Stefan M Pfister; Christof M Kramm; Nathalie Boddaert; Thomas Blauwblomme; Stéphanie Puget; Kévin Beccaria; Chris Jones; David T W Jones; Pascale Varlet; Jacques Grill; Marie-Anne Debily
Journal:  Acta Neuropathol       Date:  2020-03-19       Impact factor: 17.088

2.  Pediatric bithalamic gliomas have a distinct epigenetic signature and frequent EGFR exon 20 insertions resulting in potential sensitivity to targeted kinase inhibition.

Authors:  Gourish Mondal; Julieann C Lee; Ajay Ravindranathan; Javier E Villanueva-Meyer; Quynh T Tran; Sariah J Allen; Jairo Barreto; Rohit Gupta; Pamela Doo; Jessica Van Ziffle; Courtney Onodera; Patrick Devine; James P Grenert; David Samuel; Rong Li; Laura K Metrock; Lee-Way Jin; Reuben Antony; Mouied Alashari; Samuel Cheshier; Nicholas S Whipple; Carol Bruggers; Corey Raffel; Nalin Gupta; Cassie N Kline; Alyssa Reddy; Anu Banerjee; Matthew D Hall; Minesh P Mehta; Ziad Khatib; Ossama M Maher; Carole Brathwaite; Melike Pekmezci; Joanna J Phillips; Andrew W Bollen; Tarik Tihan; John T Lucas; Alberto Broniscer; Mitchel S Berger; Arie Perry; Brent A Orr; David A Solomon
Journal:  Acta Neuropathol       Date:  2020-04-17       Impact factor: 17.088

3.  H3 G34-mutant high-grade glioma.

Authors:  Ka Young Lim; Jae Kyung Won; Chul-Kee Park; Seung-Ki Kim; Seung Hong Choi; Taemin Kim; Hongseok Yun; Sung-Hye Park
Journal:  Brain Tumor Pathol       Date:  2020-09-29       Impact factor: 3.298
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.